AstraZeneca’s Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) ...